Tech Company Financing Transactions
DermBiont Funding Round
On 12/22/2021, DermBiont announced $28 million in Series A financing from Civilization Ventures, Olive Tree Capital and Pivotal bioVenture Partners.
Transaction Overview
Company Name
Announced On
12/22/2021
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Kneeland St. 14th Floor
Boston, MA 02118
USA
Boston, MA 02118
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
DermBiont develops skin microbiome therapeutics platform to treat and prevent skin diseases. DermBiont is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Karl Beutner
Chief Financial Officer
Max Dawson
Chief Medical Officer
Shilpa Goel
Chief Scientific Officer
Robert Brucker
VP - Bus. Development
Nick Eliovits
VP - Operations
Sanjay Jain
VP - Operations
Deryck Wade
VP - R & D
Xuecheng Zhang
Browse more venture capital transactions:
Prev: 12/22/2021: ADDI venture capital transaction
Next: 12/22/2021: Zepto venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC transactions reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs